<DOC>
	<DOCNO>NCT01218204</DOCNO>
	<brief_summary>This study investigate safety , pharmacokinetics effect GSK1292263 take alone co-dosed atorvastatin subject dyslipidemia .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics Pharmacodynamics Administering Multiple Oral Doses GSK1292263 Alone With Atorvastatin</brief_title>
	<detailed_description>This compound study healthy subject subject type II diabetes studied subject dyslipidemia . Because many patient dyslipidemia statin , important study GSK1292263 behave take potent statin , atorvastatin . The cholesterol lower drug , ezetimibe , include comparison .</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Healthy adult male females nonchildbearingpotential , aged 1875 year capable give informed consent . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea . In questionable case , blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 140 pmol/L ) confirmatory absence clear postmenopausal history . Females hormone replacement therapy ( HRT ) must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study . Male subject must agree use one contraception method list protocol . This criterion must follow time first dose study medication seven day follow last dose . Body weight &gt; 50 kg ( 110 pound ) body mass index ( BMI ) 19.0 39.0 ( inclusive ) . Part A : ( ) Subjects 80mg 40mg atorvastatin &gt; = 4 week tolerate drug well , ( ii ) Subjects lipidmodifying therapy fast low density lipoprotein cholesterol ( LDLc ) &gt; = 130mg/dL . In Part B Screening : Subjects statins Vytorin treatment &gt; = 4 week . Part B end 4 week washout : Subjects fast LDL cholesterol &gt; =120mg/dL &lt; =180mg/dL fast triglyceride &gt; =100mg/dL &lt; =400mg/dL . Part B end 4 week runin atorvastatin : Subjects tolerate well atorvastatin 10mg 80mg ( determine Investigator ) . Part B : Subjects must willing discontinue statins Vytorin duration study . Liver enzymes , AST ALT &lt; 2x upper limit normal ( ULN ) ; alkaline phosphatase bilirubin = &lt; 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Subjects Gilbert 's syndrome allow participate study . Average QTcB QTcF &lt; 450msec ; QTc &lt; 480msec subject right bundle branch block . A medical history following : Clinical angiographic cardiovascular disease , include history current evidence coronary heart disease , heart failure , cerebrovascular disease ( include stroke transient ischemic attack [ ministroke ] ) , peripheral vascular disease . Subjects pending diagnostic procedure condition time screen eligible participation . Homozygous familial hypercholesterolemia family history familial hypercholesterolemia ( Part B ) . Note : Subjects heterozygous familial hypercholesterolemia 80mg atorvastatin tolerate drug well fulfill eligibility criterion may participate Part A . History recurrent unexplained muscle ache ( e.g. , fibromyalgia ) , myopathy myositis , whether related treatment statin lipid modify drug . Renal impairment define calculated glomerular filtration rate &lt; 60 mL/min History diabetes mellitus , history postprandial and/or random blood glucose &gt; 200 mg/dl fast glucose &gt; 125 mg/dL currently take diabetes medication manage fast glucose level ( e.g. , thiazolidinediones , sulfonylurea , insulin , metformin ) . History pancreatitis within 10 year screen . Any concurrent serious illness ( e.g. , severe chronic obstructive pulmonary disease , sleep apnea , history malignancy skin cancer within 5 year initial diagnosis evidence recurrence ) may interfere subject complete study . Current chronic history liver disease , know hepatic biliary abnormality . Active peptic ulcer disease and/or history peptic ulcer disease gastrointestinal bleeding within 12 month prior screen . History kidney stone within 10 year screen . History uncorrected thyroid dysfunction abnormal thyroid function test assess thyroid stimulate hormone ( TSH ) Screening . ( NOTE : subject hypothyroidism stable dose thyroid replacement therapy least 3 month prior screen screen TSH within normal range may participate . ) Symptomatic cholelithiasis obstructive inflammatory gallbladder disease within 3 month prior screen . Gastrointestinal disease could affect fat bile acid absorption , pharmacokinetics pharmacodynamics study drug , include inflammatory bowel disease , chronic diarrhea , Crohn 's disease malabsorption syndrome within past year . Gastrointestinal surgery may affect pharmacokinetics pharmacodynamics study drug . Note : Subjects may enrol study cholecystectomy three month time screen stable asymptomatic . Subjects take ezetimibe monotherapy , fibrates , bile acid binding resin , nicotinic acid fat absorption inhibitor eligible Parts A B . For female hemoglobin &lt; 11.5g/dL , male hemoglobin &lt; 12.5g/dL . Current inadequately control hypertension ( blood pressure &gt; = 160mmHg systolic &gt; = 100mmHg diastolic screen ) . If blood pressure medication change result screening , blood pressure remeasured 6 week must meet criterion . Significant electrocardiogram ( ECG ) abnormality , define follow : Heart Rate &lt; 50 &gt; 100bpm PR Interval &lt; 120 &gt; 220ms QRS duration &lt; 70 &gt; 120ms QTC Interval ( Bazett ) &gt; 450ms Or , clinically significant rhythm abnormality identify 24hour screen Holter assessment . Subjects leave bundle branch block exclude study . Subjects partial right bundle branch block may consider inclusion follow consultation GlaxoSmithKline ( GSK ) Medical Monitor . Subjects WolfParkinsonWhite ( WPW ) syndrome exclude study . Creatinine phosphokinase ( CPK ) &gt; = 2x ULN screening . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . A positive test HIV antibody . The subject positive prestudy drugofabuse screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 14 drinks/week men &gt; 7 drinks/week woman . One drink equivalent ( 12 g alcohol ) = 5 ounce ( 150 ml ) wine 12 ounce ( 360 ml ) beer 1.5 ounce ( 45 ml ) 80 proof distil spirit . Subjects exclude require treatment systemic corticosteroid . Treatment investigational drug within 30 day 5 halflives ( whichever longer ) prior dose . Exposure four new chemical entity within 12 month prior first dose day . History sensitivity untoward reaction study medication ( GSK1292263 , atorvastatin ezetimibe ) , component thereof history drug allergy , opinion physician responsible , contraindicate participation . History intolerance statin . Any change concomitant medication ( include multivitamin , herbal remedy , dietary supplement , overthecounter medication ) within six week prior screen approve GSK . On diet may affect study outcome , change diet , exercise habit smoke status within six week prior screen plan change study ( e.g. , new exercise program ) dietary instruction Study Procedures Manual . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . Where participation study would result donation blood excess approximately 500mL within 56 day period . Subject mentally legally incapacitate . Unwillingness inability follow procedure outline protocol . Pregnant female determine positive urine hCG test screen prior dosing . Lactating female . History sensitivity heparin heparininduced thrombocytopenia . Consumption red wine , Seville oranges , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication . Unwilling abstain caffeineor xanthinecontaining product Day 2 Day 15 . Subject either immediate family member participate investigator , study coordinator , employee investigator ; member staff conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Dyslipidemia</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Safety</keyword>
	<keyword>Ezetimibe</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Lipids</keyword>
	<keyword>Statin</keyword>
	<keyword>Atorvastatin</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>GSK1292263</keyword>
</DOC>